Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2E1 | P05181 | 1/20 | 0.56 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.56 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | NR2E1 | Q9Y466 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.44 |
| ▸ | NOS2 | P35228 | 1/20 | 0.44 |
| ▸ | MAOA | P21397 | 4/20 | 0.43 |
| ▸ | MAOB | P27338 | 4/20 | 0.43 |
| ▸ | PDE4A | P27815 | 1/20 | 0.40 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.40 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.40 |
| ▸ | WNT3A | P56704 | 2/20 | 0.39 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.38 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27985278 | 0.80 | CYP1A2 (0.65) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL264998 | 0.79 | CYP1A2 (0.56) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22199019 | 0.79 | CYP2E1 (0.56) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL15442444 | 0.75 | NR2E1 (0.49) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL2285981 | 0.75 | CYP1A2 (0.59) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9701793 | 0.74 | NR2E1 (0.48) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3343040 | 0.74 | NR2E1 (0.48) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL10175045 | 0.74 | CYP2E1 (0.50) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL24369389 | 0.73 | CYP2E1 (0.50) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL22199099 | 0.73 | CYP2E1 (0.62) | CYP2E1CYP2A6CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 67 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3752497-B1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS INC (US) | 2024-07-17 | — | — | EP | disclosed |
| CN-112218857-B | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-110818683-B | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2023-04-14 | — | — | CN | disclosed |
| CN-114450005-A | Compounds for the treatment of neurological disorders | 星座制药公司 | 2022-05-06 | — | — | CN | disclosed |
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | CONSTELLATION PHARMACEUTICALS, INC. | 2021-04-22 | — | — | US | disclosed |
| WO-2021021893-A1 | COMPOUNDS FOR USE IN TREATING NEUROLOGICAL DISORDERS | CONSTELLATION PHARMACEUTICALS, INC. (US) | 2021-02-04 | — | — | WO | disclosed |
| CN-112218857-A | P300/CBP HAT inhibitors and methods of use thereof | 星座制药公司 | 2021-01-12 | — | — | CN | disclosed |
| EP-3752497-A1 | P300/CBP HAT INHIBITORS | Constellation Pharmaceuticals, Inc. (US) | 2020-12-23 | — | — | EP | disclosed |
| CN-110818683-A | 2-pyridine substituted urea structure small molecule compound and synthesis and application thereof | 中国科学院上海药物研究所 | 2020-02-21 | — | — | CN | disclosed |
| EP-2751104-B1 | COMPOUNDS AND COMPOSITIONS AS C-KIT KINASE INHIBITORS | NOVARTIS AG (CH) | 2019-09-25 | — | — | EP | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | ASTRAZENECA AB (SE) | 2012-05-17 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | CELLZOME LIMITED (GB) | 2012-01-26 | — | — | US | disclosed |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | IRM LLC (BM) | 2011-09-29 | — | — | US | disclosed |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | Janssen Pharmaceuticals, Inc. | 2011-09-29 | — | — | US | disclosed |
| WO-2010094647-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | ORTHO-MCNEIL-JANSSEN PHARMACEUTICALS, INC (US) | 2010-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210115008-A1 | P300/CBP HAT INHIBITORS | EP300, HDAC1, KAT2A | CYP2E1 2303/4885CYP2A6 3887/4885CYP1A2 3986/4885 |
| US-20120122843-A1 | Compounds and Their Use for Treatment of Amyloid Beta-Related Diseases | APP, BACE1, PSEN1 | CYP2E1 3006/4885CYP2A6 2517/4885CYP1A2 2143/4885 |
| US-20110237580-A1 | SUBSTITUTED BICYCLIC IMIDAZOLE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, PSEN1 | CYP2E1 959/4885CYP2A6 1725/4885CYP1A2 953/4885 |
| US-20120022090-A1 | NOVEL SUBSTITUTED BENZOXAZOLE, BENZIMIDAZOLE, OXAZOLOPYRIDINE AND IMIDAZOPYRIDINE DERIVATIVES AS GAMMA SECRETASE MODULATORS | BACE1, BACE2, GSAP | CYP2E1 452/4885CYP2A6 1000/4885CYP1A2 274/4885 |
| US-20110237573-A1 | N- (HETERO)ARYL, 2- (HETERO)ARYL-SUBSTITUTED ACETAMIDES FOR USE AS WNT SIGNALING MODULATORS | WNT1, CTNNB1, WNT3A | CYP2E1 473/4885CYP2A6 119/4885CYP1A2 103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.